MediumEndocrinologyType 2 diabetes with cardiovascular diseaseca-mccqe1ca-rcpsc-im
A 58-year-old man with established coronary artery disease and type 2 diabetes (HbA1c 7.6%) is on metformin, an ACE inhibitor, a statin, and low-dose aspirin. eGFR is 65 mL/min/1.73 m² and he has microalbuminuria. According to Diabetes Canada and CCS cardiorenal guidelines, which additional glucose-lowering agent would provide the greatest cardiovascular and renal risk reduction?